middle.news
Can Zelira’s ZLT-L-007 Revolutionize Diabetic Neuropathy Treatment?
1:57am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Can Zelira’s ZLT-L-007 Revolutionize Diabetic Neuropathy Treatment?
1:57am on Monday 2nd of June, 2025 AEST
Key Points
ZLT-L-007 monotherapy achieved 85% reduction in daily pain scores by Day 90
Combination therapy with Lyrica® showed additive benefits including full sleep interference resolution
Complete resolution of electric shock, stabbing, and burning pain with ZLT-L-007
No serious adverse events reported; safety markers remained stable
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE